CRISPR Off-Target Editing Creates Unpredictable Large Deletions and Translocations

CRISPR sometimes cuts at wrong locations in the genome that look similar to the target. Beyond point mutations, these unintended cuts can cause large deletions (megabases), inversions, and translocations — potentially activating cancer genes. This is the biggest regulatory bottleneck for expanding CRISPR therapies.

Cas9 tolerates mismatches in the PAM-distal region (positions 1-8). Off-target DSBs can cause large deletions (>1 kb, sometimes megabases), chromothripsis-like rearrangements, and translocations between on-target and off-target sites. Detection methods (GUIDE-seq, CIRCLE-seq, DISCOVER-Seq) each have sensitivity limitations and don't perfectly agree. High-fidelity Cas9 variants reduce but don't eliminate off-targets, often with reduced on-target efficiency. FDA issued specific guidance on off-target assessment for gene editing INDs (2024).

Why It Matters

FDA placed clinical holds on gene editing programs over genotoxicity. Casgevy (approved Dec 2023) required extensive off-target profiling and long-term follow-up. For in vivo CRISPR (editing billions of cells inside patients), comprehensive off-target assessment is essentially impossible pre-treatment.

Startup Approach

Build comprehensive off-target profiling platform as CRO service (regulatory requirement for IND filing). Or develop next-gen editors with inherently higher specificity. Or develop 'kill switches' and temporally controlled editors limiting exposure time.

NIH Funding

SCGE Consortium funded off-target detection assays. NHGRI funds CRISPR safety. NCI funds genotoxicity assessment. Estimated $50-100M in active NIH funding on CRISPR safety.

Who's Working On It

J. Keith Joung lab (Harvard, GUIDE-seq, HiFi Cas9), David Liu lab (Broad, base/prime editors avoiding DSBs), Caribou Biosciences (chRDNA guides), Jennifer Doudna lab (anti-CRISPR proteins)